Law360, New York (October 04, 2012, 8:48 PM ET) -- The Federal Trade Commission on Thursday asked the U.S. Supreme Court to review the dismissal of the agency's antitrust challenge to patent settlements Solvay Pharmaceuticals Inc. had penned with several generics makers to protect its blockbuster drug Androgel.
The U.S. solicitor general filed a petition for certiorari on the FTC's behalf, urging the high court to take the case to resolve a circuit split over whether pay-for-delay pharmaceutical patent settlements are generally legal, as the Eleventh Circuit held in this case, or presumptively anti-competitive, as the...
FTC Takes Androgel Pay-For-Delay Case To High Court
To view the full article, take a free trial now.
